癫痫发作、驾驶执照与医疗报告更新:美国神经病学学会立场声明
美国神经病学学会、美国癫痫学会和美国癫痫基金会更新了1994年和2007年关于癫痫发作、驾驶执照和医疗报告的立场声明。共识包括:美国应通过统一法律委员会等系统制定国家驾驶标准;州许可标准应由医学顾问委员会与机动车管理部门合作制定;所有病例通常应要求至少3个月无癫痫发作期方可驾驶;特定诱发性发作或短期中断药物者可能无需无发作期;允许但非强制报告高风险驾驶者,报告或不报告均不承担法律责任。
要点
- 所有病例通常应要求至少3个月无癫痫发作期方可驾驶,医学顾问委员会可根据有利和不利特征个体化延长。
- 仅由未来不太可能复发的诱发因素导致的诱发性发作个体,恢复驾驶前可能无需无发作期。
- 允许但非强制报告高风险驾驶者,报告或不报告均不承担法律责任。
核心结论
- 美国神经病学学会、美国癫痫学会和美国癫痫基金会发布共识立场声明,更新1994年和2007年关于癫痫发作、驾驶执照和医疗报告的立场。
研究设计与样本
- 美国神经病学学会、美国癫痫学会和美国癫痫基金会共同制定的共识立场声明。
主要发现
- 共识包括11项立场,涉及国家驾驶标准、州许可标准制定、公平无歧视标准、无发作期要求、特定情况豁免、驾驶暂停、认知或协调受损者避免驾驶、医疗报告自愿性及法律责任豁免、替代交通方式等。
关键数值与推荐
- 所有病例通常应要求至少3个月无癫痫发作期方可驾驶,并可由医学顾问委员会根据有利和不利特征个体化延长。
- 仅由未来不太可能复发的诱发因素导致的诱发性发作个体,恢复驾驶前可能无需无发作期。
- 因住院或医生指导的药物滴定导致短期中断抗癫痫药物而发作的既往控制良好癫痫患者,在恢复既往有效抗癫痫药物水平后,驾驶前可能无需无发作期。
- 在减量及停用抗癫痫药物后未引入其他抗癫痫药物期间,患者和医生应暂停驾驶。
- 因预防发作药物导致认知或协调受损的个体应避免驾驶。
临床怎么用
- 所有病例通常应要求至少3个月无癫痫发作期方可驾驶。
- 仅由未来不太可能复发的诱发因素导致的诱发性发作个体,恢复驾驶前可能无需无发作期。
- 因住院或医生指导的药物滴定导致短期中断抗癫痫药物而发作的既往控制良好癫痫患者,在恢复既往有效抗癫痫药物水平后,驾驶前可能无需无发作期。
- 在减量及停用抗癫痫药物后未引入其他抗癫痫药物期间,患者和医生应暂停驾驶。
- 因预防发作药物导致认知或协调受损的个体应避免驾驶。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This consensus position statement of the American Academy of Neurology, American Epilepsy Society, and Epilepsy Foundation of America updates prior 1994 and 2007 position statements on seizures, driver licensure, and medical reporting. Key consensus positions include the following: (1) in the United States, national driving standards promulgated through a system such as the Uniform Law Commission would reduce confusion and improve adherence with state driving standards; (2) state licensing criteria for medical conditions should be promulgated by regulations and guidelines based on enabling legislation rather than in statutes themselves and should be developed by medical advisory boards working in collaboration with departments of motor vehicles; (3) licensing criteria should be equitable, nondiscriminatory, objective, and compatible with comparable risks in other populations; (4) a minimum seizure-free interval of 3 months should ordinarily be required before driving in all cases and should be extended in individual cases based on review of favorable and unfavorable features by medical advisory boards; (5) individuals with exclusively provoked seizures attributable to provoking factors that are unlikely to reoccur in the future may not require a seizure-free interval before resuming driving; (6) individuals with previously well-controlled epilepsy who experience seizures due to short-term interruptions of antiseizure medications in the setting of hospitalization or practitioner-directed medication-titration may not require a seizure-free interval before driving once previously effective levels of antiseizure medications have been resumed; (7) patients and practitioners should pause driving during tapering and following discontinuation of an antiseizure medication if another such medication is not introduced; (8) individuals whose cognition or coordination is impaired due to medications used to prevent seizures should refrain from driving; (9) health care practitioners should be allowed but not mandated to report drivers who pose an elevated risk; but (10) neither a decision to report a patient suspected of being at elevated risk nor a decision declining to report a patient suspected of being at elevated risk should be subject to legal liability; (11) nations, states, and municipalities should provide alternative methods of transportation and accommodations for individuals whose driving privileges are restricted due to medical conditions.
引用
- Tolchin B, Krauss GL, Spanaki MV, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology. 2025. PMID: 40073306. doi:10.1212/WNL.0000000000213459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。